235 related articles for article (PubMed ID: 19915146)
1. Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants.
Wu H; Shekar SC; Flinn RJ; El-Sibai M; Jaiswal BS; Sen KI; Janakiraman V; Seshagiri S; Gerfen GJ; Girvin ME; Backer JM
Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20258-63. PubMed ID: 19915146
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit.
Shekar SC; Wu H; Fu Z; Yip SC; Nagajyothi ; Cahill SM; Girvin ME; Backer JM
J Biol Chem; 2005 Jul; 280(30):27850-5. PubMed ID: 15932879
[TBL] [Abstract][Full Text] [Related]
3. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.
Dbouk HA; Pang H; Fiser A; Backer JM
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):19897-902. PubMed ID: 21030680
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains.
Yu J; Wjasow C; Backer JM
J Biol Chem; 1998 Nov; 273(46):30199-203. PubMed ID: 9804776
[TBL] [Abstract][Full Text] [Related]
5. The structure of p85ni in class IA phosphoinositide 3-kinase exhibits interdomain disorder.
Sen KI; Wu H; Backer JM; Gerfen GJ
Biochemistry; 2010 Mar; 49(10):2159-66. PubMed ID: 20131869
[TBL] [Abstract][Full Text] [Related]
6. The iSH2 domain of PI 3-kinase is a rigid tether for p110 and not a conformational switch.
Fu Z; Aronoff-Spencer E; Wu H; Gerfen GJ; Backer JM
Arch Biochem Biophys; 2004 Dec; 432(2):244-51. PubMed ID: 15542063
[TBL] [Abstract][Full Text] [Related]
7. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
[TBL] [Abstract][Full Text] [Related]
8. Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects.
Gabelli SB; Echeverria I; Alexander M; Duong-Ly KC; Chaves-Moreira D; Brower ET; Vogelstein B; Amzel LM
Biophys Rev; 2014 Mar; 6(1):89-95. PubMed ID: 25309634
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).
Burke JE; Perisic O; Masson GR; Vadas O; Williams RL
Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15259-64. PubMed ID: 22949682
[TBL] [Abstract][Full Text] [Related]
10. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
[TBL] [Abstract][Full Text] [Related]
11. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
[TBL] [Abstract][Full Text] [Related]
12. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
Zhao L; Vogt PK
Cell Cycle; 2010 Feb; 9(3):596-600. PubMed ID: 20009532
[TBL] [Abstract][Full Text] [Related]
13. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
Huang CH; Mandelker D; Gabelli SB; Amzel LM
Cell Cycle; 2008 May; 7(9):1151-6. PubMed ID: 18418043
[TBL] [Abstract][Full Text] [Related]
14. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
Pang H; Flinn R; Patsialou A; Wyckoff J; Roussos ET; Wu H; Pozzuto M; Goswami S; Condeelis JS; Bresnick AR; Segall JE; Backer JM
Cancer Res; 2009 Dec; 69(23):8868-76. PubMed ID: 19903845
[TBL] [Abstract][Full Text] [Related]
15. N-terminal domains of the class ia phosphoinositide 3-kinase regulatory subunit play a role in cytoskeletal but not mitogenic signaling.
Hill KM; Huang Y; Yip SC; Yu J; Segall JE; Backer JM
J Biol Chem; 2001 May; 276(19):16374-8. PubMed ID: 11278326
[TBL] [Abstract][Full Text] [Related]
16. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
Jaiswal BS; Janakiraman V; Kljavin NM; Chaudhuri S; Stern HM; Wang W; Kan Z; Dbouk HA; Peters BA; Waring P; Dela Vega T; Kenski DM; Bowman KK; Lorenzo M; Li H; Wu J; Modrusan Z; Stinson J; Eby M; Yue P; Kaminker JS; de Sauvage FJ; Backer JM; Seshagiri S
Cancer Cell; 2009 Dec; 16(6):463-74. PubMed ID: 19962665
[TBL] [Abstract][Full Text] [Related]
17. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
[TBL] [Abstract][Full Text] [Related]
18. Insights into the pathological mechanisms of p85α mutations using a yeast-based phosphatidylinositol 3-kinase model.
Oliver MD; Fernández-Acero T; Luna S; Rodríguez-Escudero I; Molina M; Pulido R; Cid VJ
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28143957
[TBL] [Abstract][Full Text] [Related]
19. Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS).
Burke JE; Williams RL
Adv Biol Regul; 2013 Jan; 53(1):97-110. PubMed ID: 23194976
[TBL] [Abstract][Full Text] [Related]
20. Human tumor mutants in the p110alpha subunit of PI3K.
Liu Z; Roberts TM
Cell Cycle; 2006 Apr; 5(7):675-7. PubMed ID: 16627990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
